We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Kite Pharmaceuticals, Inc.'s financial performance into perspective.
Aug 28, 2017
Aug 17, 2017
Kite Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3